Printer Friendly

RHONE-POULENC RORER AND BOLAR RESTRUCTURE AGREEMENT ON DILTIAZEM IMMEDIATE AND SUSTAINED RELEASE FORMULATIONS

 RHONE-POULENC RORER AND BOLAR RESTRUCTURE AGREEMENT ON
 DILTIAZEM IMMEDIATE AND SUSTAINED RELEASE FORMULATIONS
 COLLEGEVILLE, Pa., and COPIAGUE, N.Y., May 29 /PRNewswire/ -- Rhone-Poulenc Rorer Inc. (NYSE: RPR) and Bolar Pharmaceutical Co. (AMEX: BLR) announce the restructuring of their agreement concerning the immediate release and sustained release formulations of diltiazem, a calcium channel blocker indicated for treatment of hypertension.
 Both forms of the drug are currently pending FDA approval.
 Under the new agreement, Bolar will assume sole responsibility for the manufacture and marketing of the immediate release formulation and will retain all profits realized if approval is obtained. RPR will maintain sole responsibility for the manufacturing, marketing and clinical development of Dilacor(TM) XR, the once-daily, sustained release formulation of the product. Both companies will continue to share the profits from this product, with RPR receiving additional consideration for having granted all rights to potential profits from the immediate release product to Bolar.
 The restructured agreement benefits both companies by ensuring that each is responsible for the product which has the best strategic fit with the company's overall objectives.
 /delval/
 -0- 5/29/92
 /CONTACT: Rhone-Poulenc Rorer media relations, 215-454-3871, or investor relations, 215-454-3851, or Bolar Pharmaceuticals, 516-842-8383 (media), or 516-842-8383 (investors)/
 (RPR BLR) CO: Rhone-Poulenc Rorer Inc.; Bolar Pharmaceuticals, Co. ST: Pennsylvania IN: MTC SU:


JS-CC -- PH016 -- 5145 05/29/92 11:13 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:May 29, 1992
Words:224
Previous Article:SHAW INDUSTRIES COMPLETES ACQUISITION OF SALEM CARPET MILLS
Next Article:NISSAN REPORTS FINANCIAL RESULTS FOR FISCAL 1992
Topics:


Related Articles
WARNER-LAMBERT, RHONE-POULENC RORER AGREE TO CO-DEVELOP AND CO-PROMOTE ADVANCED QUINOLONE ANTIBACTERIAL IN U.S. AND CANADA
RHONE-POULENC RORER AND CHUGAI TO CO-DEVELOP, CO-MARKET TAXOTERE(R) FOR JAPAN
RHONE-POULENC RORER AND NOVEN PHARMACEUTICALS SIGN LICENSING AGREEMENT FOR TRANSDERMAL HORMONE REPLACEMENT THERAPY PRODUCTS
SANOFI WINTHROP AND RHONE-POULENC RORER INC. SIGN MARKETING, DISTRIBUTION AGREEMENT FOR ANTI-ANGINAL
RHONE-POULENC RORER AND FISONS ANNOUNCE AGREEMENT IN PRINCIPLE TO CO-PROMOTE TILADE(R) AND AZMACORT(R)
RHONE-POULENC RORER AND FISONS ANNOUNCE AGREEMENT IN PRINCIPLE TO CO-PROMOTE TILADE(R) AND AZMACORT(R)
THE IMMUNE RESPONSE CORPORATION REGAINS ALL RIGHTS TO HIV IMMUNOTHERAPEUTIC FROM RHONE-POULENC RORER INC.
Rhone-Poulenc Rorer Inc. to Evaluate NanoSystems Drug Delivery Technology For Asthma
Advanced Polymer Systems Announces Expanded Agreement With Dermik Laboratories And Initiation of Phase III Study of Microsponge(R)-Entrapped...

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters